Concordance of transcriptional and apical benchmark dose levels for conazole-induced liver effects in mice

Toxicological Sciences

Volumn 136, Issue 1, 2013, Pages 205-215

  Bhat, Virunya S ^a   Hester, Susan D ^b   Nesnow, Stephen ^c   Eastmond, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c NONE

Author keywords

Benchmark dose; Conazole; Liver; Phenotypic anchoring.; Transcriptional dose response

Indexed keywords

CYPROCONAZOLE; CYTOCHROME P450; EPOXICONAZOLE; FUNGICIDE; GLUTATHIONE; MYCLOBUTANIL; PROPICONAZOLE; TRIADIMEFON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DETOXIFICATION; GENE EXPRESSION; LIPID OXIDATION; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER HYPERTROPHY; MALE; METABOLISM; MOUSE; NONHUMAN; OXIDATIVE STRESS; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS;

BENCHMARK DOSE; CONAZOLE; LIVER; PHENOTYPIC ANCHORING.; TRANSCRIPTIONAL DOSE RESPONSE;

ANIMALS; BENCHMARKING; CARCINOGENICITY TESTS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DATABASES, GENETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; LIVER; LIVER NEOPLASMS; MALE; MICE; MODELS, GENETIC; MODELS, STATISTICAL; MOLECULAR STRUCTURE; PHENOTYPE; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 84887987005     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft182     Document Type: Article

References (52)

1. Allen, J. W., Wolf, D. C., George, M. H., Hester, S. D., Sun, G., Thai, S. F., Delker, D. A., Moore, T., Jones, C., Nelson, G., et al. (2006). Toxicity profiles in mice treated with hepatotumorigenic and non-hepatotumorigenic triazole conazole fungicides: Propiconazole, triadimefon, and myclobutanil. Toxicol. Pathol. 34, 853-862.
2. Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R. D., Mount, D. R., Nichols, J. W., Russom, C. L., Schmieder, P. K., et al. (2010). Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 29, 730-741.
3. Auerbach, S. S., Shah, R. R., Mav, D., Smith, C. S., Walker, N. J., Vallant, M. K., Boorman, G. A., and Irwin, R. D. (2010). Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol. Appl. Pharmacol. 243, 300-314.
4. California Department of Food and Agriculture. (2000). Medical Toxicology Branch. Summary of Toxicology Data. Myclobutanil. SB 950-(not assigned), Tolerance # 51315 Chemical Code #: 2245. Original version 02/03/1987. Last updated September 21, 2000.
5. Chiu, W. A., Euling, S. Y., Scott, C. S., and Subramaniam, R. P. (2010). Approaches to advancing quantitative human health risk assessment of environmental chemicals in the post-genomic era. Toxicol. Appl. Pharmacol. (forthcoming).
6. Choe, S. E., Boutros, M., Michelson, A. M., Church, G. M., and Halfon, M. S. (2005). Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 6, R16.
7. Davis, J. A., Gift, J. S., and Zhao, Q. J. (2011). Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1. Toxicol. Appl. Pharmacol. 254, 181-191.
8. Dellarco, V., Henry, T., Sayre, P., Seed, J., and Bradbury, S. (2010). Meeting the common needs of a more effective and efficient testing and assessment paradigm for chemical risk management. J. Toxicol. Environ. Health. B. Crit. Rev. 13, 347-360.
9. Dewhurst, I., and Dellarco, V. (2004). In International Programme on Chemical Safety Joint FAO/WHO Meeting on Pesticide Residues in Food. Available at: http://whqlibdoc.who.int/publications/2006/9241665203_eng.pdf
10. Edwards, S. W., and Preston, R. J. (2008). Systems biology and mode of action based risk assessment. Toxicol. Sci. 106, 312-318.
11. Ellinger-Ziegelbauer, H., Gmuender, H., Bandenburg, A., and Ahr, H. J. (2008). Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637, 23-39.
12. Fielden, M. R., Adai, A., Dunn, R. T., 2nd, Olaharski, A., Searfoss, G., Sina, J., Aubrecht, J., Boitier, E., Nioi, P., Auerbach, S., et al.; Predictive Safety Testing Consortium, Carcinogenicity Working Group. (2011). Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat. Toxicol. Sci. 124, 54-74.
13. Hamadeh, H. K., Bushel, P. R., Jayadev, S., DiSorbo, O., Bennett, L., Li, L., Tennant, R., Stoll, R., Barrett, J. C., Paules, R. S., et al. (2002). Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67, 232-240.
14. Hannas, B. R., Lambright, C. S., Furr, J., Evans, N., Foster, P. M., Gray, E. L., and Wilson, V. S. (2012). Genomic biomarkers of phthalate-induced male reproductive developmental toxicity: A targeted RT-PCR array approach for defining relative potency. Toxicol. Sci. 125, 544-557.
15. Hester, S., Moore, T., Padgett, W. T., Murphy, L., Wood, C. E., and Nesnow, S. (2012). The hepatocarcinogenic conazoles: Cyproconazole, epoxiconazole, and propiconazole induce a common set of toxicological and transcriptional responses. Toxicol. Sci. 127, 54-65.
16. INCHEM (1992). Monograph 847. Myclobutanil (Pesticide residues in food: 1992 evaluations Part II Toxicology). Available at: http://www.inchem.org/ documents/jmpr/jmpmono/v92pr13.htm
17. Jia, G., Takahashi, R., Zhang, Z., Tsuji, Y., and Sone, H. (2006). Aldo-keto reductase 1 family B7 is the gene induced in response to oxidative stress in the livers of Long-Evans Cinnamon rats. Int. J. Oncol. 29, 829-838.
18. Julien, E., Boobis, A. R., and Olin, S. S.; Ilsi Research Foundation Threshold Working Group. (2009). The Key Events Dose-Response Framework: A cross-disciplinary mode-of-action based approach to examining doseresponse and thresholds. Crit. Rev. Food Sci. Nutr. 49, 682-689.
19. Kopec, A. K., Burgoon, L. D., Ibrahim-Aibo, D., Burg, A. R., Lee, A. W., Tashiro, C., Potter, D., Sharratt, B., Harkema, J. R., Rowlands, J. C., et al. (2010). Automated dose-response analysis and comparative toxicogenomic evaluation of the hepatic effects elicited by TCDD, TCDF, and PCB126 in C57BL/6 mice. Toxicol. Sci. 118, 286-297.
20. Liu, M. J., Takahashi, Y., Wada, T., He, J., Gao, J., Tian, Y., Li, S., and Xie, W. (2009). The aldo-keto reductase Akr1b7 gene is a common transcriptional target of xenobiotic receptors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 76, 604-611.
21. Lubet, R. A., Mayer, R. T., Cameron, J. W., Nims, R. W., Burke, M. D., Wolff, T., and Guengerich, F. P. (1985). Dealkylation of pentoxyresorufin: A rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys. 238, 43-48.
22. Manuppello, J., and Willett, C. (2008). Longer rodent bioassay fails to address 2-year bioassay's flaws. Environ. Health Perspect. 116, A516-7; author reply A517.
23. National Research Council (NRC). (2007a). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academy Press, Washington, DC.
24. National Research Council (NRC). (2007b). Applications of Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment. National Academy Press, Washington, DC.
25. National Research Council (NRC). (2009). Science and Decisions: Advancing Risk Assessment. National Academy Press, Washington, DC.
26. Nesnow, S. (2013). Integration of toxicological approaches with "omic" and related technologies to elucidate mechanisms of carcinogenic action: Propiconazole, an example. Cancer Lett. 334, 20-27.
27. Nesnow, S., Ward, W., Moore, T., Ren, H., and Hester, S. D. (2009). Discrimination of tumorigenic triazole conazoles from phenobarbital by transcriptional analyses of mouse liver gene expression. Toxicol. Sci. 110, 68-83.
28. OECD (2007). OECD Environment Health and Safety Publications Series on Testing and Assessment No. 80. Guidance on grouping of chemicals. Environment Directorate, Paris 2007. http://www.oecd.org/officialdocuments/ displaydocumentpdf/?cote=env/jm/mono(2007)28&doclanguage=en
29. Paules, R. (2003). Phenotypic anchoring: Linking cause and effect. Environ. Health Perspect. 111, A338-A339.
30. Peffer, R. C. (2011). Cyproconazole Syngenta Response to the Proposed Inclusion of Cyproconazole on the List of Chemicals Submitted to the Carcinogen Identification Committee (July 2011). Available at: http:// www.oehha.org/prop65/public_meetings/CIC101211/comments/prior/ SyngentaCyproconazoleStubs.pdf
31. Ross, J., Plummer, S. M., Rode, A., Scheer, N., Bower, C. C., Vogel, O., Henderson, C. J., Wolf, C. R., and Elcombe, C. R. (2010). Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol. Sci. 116, 452-466.
32. Schmidt, D. R., Schmidt, S., Holmstrom, S. R., Makishima, M., Yu, R. T., Cummins, C. L., Mangelsdorf, D. J., and Kliewer, S. A. (2011). AKR1B7 is induced by the farnesoid X receptor and metabolizes bile acids. J. Biol. Chem. 286, 2425-2432.
33. Slikker, W., Jr, Andersen, M. E., Bogdanffy, M. S., Bus, J. S., Cohen, S. D., Conolly, R. B., David, R. M., Doerrer, N. G., Dorman, D. C., Gaylor, D. W., et al. (2004). Dose-dependent transitions in mechanisms of toxicity: Case studies. Toxicol. Appl. Pharmacol. 201, 226-294.
34. Thomas, R. S., Allen, B. C., Nong, A., Yang, L., Bermudez, E., Clewell, H. J., 3rd, and Andersen, M. E. (2007a). A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol. Sci. 98, 240-248.
35. Thomas, R. S., Pluta, L., Yang, L., and Halsey, T. A. (2007b). Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays. Toxicol. Sci. 97, 55-64.
36. U.S. Environmental Protection Agency (EPA). (1990). Memorandum: Cyproconazole-mouse carcinogenicity study. OPTS-128993-018. June 1990. MRID: 411472-01.
37. U.S. Environmental Protection Agency (EPA). (2000). Myclobutanil Pesticide Tolerance. OPP-300994; FRL-6555-5. Available at: http://www.epa.gov/ fedrgstr/EPA-PEST/2000/May/Day-10/p11571.htm. Accessed May 2000.
38. U.S. Environmental Protection Agency (EPA). (2001). Epoxiconazole-Report of the Cancer Assessment Review Committee. Office of Prevention, Pesticides and Toxic Substances. PC Code 123909. January 2001.
39. U.S. Environmental Protection Agency (EPA). (2002). A Review of the Reference Dose and Reference Concentration Process. EPA/630/P-02/002F. 01 Dec 2002. U.S. EPA, Risk Assessment Forum, Washington, DC. Available at: http://www.epa.gov/raf/pubhumanhealth.htm
40. U.S. Environmental Protection Agency (EPA). (2005). Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001B. March 2005. Available at: http://cfpub.epa.gov/ncea/raf/recordisplay.cfm?deid=116283
41. U.S. Environmental Protection Agency (EPA). (2006a). Reregistration Eligibility Decision (RED) for Propiconazole. EPA 738R-06-27. Available at: http:// www.epa.gov/oppsrrd1/REDs/propiconazole_red.pdf. Accessed July 2006.
42. U.S. Environmental Protection Agency (EPA). (2006b). Reregistration Eligibility Decision (RED) for Triadimefon and Tolerance Reassessment for Triadimenol. EPA 738-R-06-003. Available at: http://www.epa.gov/oppsrrd1/REDs/triadimefon_red.pdf. Accessed August 2006.
43. U.S. Environmental Protection Agency (EPA). (2006c). Epoxiconazole Pesticide Tolerance. EPA-HQ-OPP-2005-0071; FRL-8080-9]. Available at: http://www.regulations.gov. Accessed September 2006.
44. U.S. Environmental Protection Agency (EPA). (2008). Cyproconazole Pesticide Tolerance. EPA-HQ-OPP-2008-0149; [FRL-8362-9]. Available at: http://www.regulations.gov/#!documentDetail;D=EPA-HQOPP-2008-0149-0001. Accessed May 2008.
45. U.S. Environmental Protection Agency (EPA). (2011a). Framework for an EPA Chemical Safety for Sustainability Research Program. Office of Research and Development, Washington, DC.
46. U.S. Environmental Protection Agency (EPA). (2011b). APPENDIX A & B. Use of "Omic" Technology to Inform the Risk Assessment. Support Document for Case Study: Propiconazole. EPA-HQ-OPP-2011-0284-0003.
47. U.S. Environmental Protection Agency (EPA). (2012a). Benchmark Dose Technical Guidance. Risk Assessment Forum. EPA/100/R-12/001. Available at: http://www.epa.gov/raf/publications/benchmarkdose.htm. Accessed June 2012.
48. U.S. Environmental Protection Agency (EPA). (2012b). Benchmark Dose Software (BMDS) version 2.3.1. National Center for Environmental Assesment, Washington, DC. Available at: http://www.epa.gov/ncea/bmds/ index.html. Accessed September 28, 2012.
49. Volat, F. E., Pointud, J. C., Pastel, E., Morio, B., Sion, B., Hamard, G., Guichardant, M., Colas, R., Lefrançois-Martinez, A. M., and Martinez, A. (2012). Depressed levels of prostaglandin F2a in mice lacking Akr1b7 increase basal adiposity and predispose to diet-induced obesity. Diabetes 61, 2796-2806.
50. Ward, W. O., Delker, D. A., Hester, S. D., Thai, S. F., Wolf, D. C., Allen, J. W., and Nesnow, S. (2006). Transcriptional profiles in liver from mice treated with hepatotumorigenic and nonhepatotumorigenic triazole conazole fungicides: Propiconazole, triadimefon, and myclobutanil. Toxicol. Pathol. 34, 863-878.
51. Yang, L., Allen, B. C., and Thomas, R. S. (2007). BMDExpress: A software tool for the benchmark dose analyses of genomic data. BMC Genomics 8, 387.
52. Yu, X., Griffith, W. C., Hanspers, K., Dillman, J. F., 3rd, Ong, H., Vredevoogd, M. A., and Faustman, E. M. (2006). A system-based approach to interpret dose-and time-dependent microarray data: Quantitative integration of gene ontology analysis for risk assessment. Toxicol. Sci. 92, 560-577.